title: [Reevaluation of MAB therapy and progress of endocrine therapy].
authors.forename: Laurence
authors.initials: L
authors.lastname: Klotz
authors.forename: Heather
authors.initials: H
authors.lastname: Payne
authors.forename: David
authors.initials: D
authors.lastname: Gillatt
authors.forename: Thomas
authors.initials: T
authors.lastname: Keane
authors.forename: Clive
authors.initials: C
authors.lastname: Morris
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
authors.lastname: Hirao
authors.forename: Koichiro
authors.initials: K
authors.lastname: Akakura
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukagai
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000813:Anilides / Q000008:administration & dosage / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D009570:Nitriles; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D015996:Survival Rate; D014105:Tosyl Compounds
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D017273:Goserelin; C053541:bicalutamide; D017430:Prostate-Specific Antigen